|
pubmed:abstractText |
Specific therapy for non-alcoholic steatohepatitis (NASH) is needed because of the potential severity of this liver disease. NASH is a recognized cause of cryptogenic cirrhosis and, increasingly, of hepatocellular carcinoma. Therefore, there is an unmet medical need for the therapy of NASH. This article discusses this therapy, with particular emphasis on pharmacologic therapy.
|
|
pubmed:affiliation |
Université Pierre et Marie Curie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié Salpêtrière, 47-83 Bd de l'Hôpital, Paris 75013, France. vratziu@teaser.fr
|
